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Abstract
Background: Pneumococcal infections cause major morbidity and mortality in developing countries. We report the
epidemiology of S. pneumoniae carriage in a developing region, the Gaza strip, and evaluate the theoretical coverage of
carriage strains by pneumococcal conjugate vaccines (PCVs).
Methodology: In 2009 we conducted a cross-sectional survey of S. pneumoniae carriage in healthy children and their
parents, living throughout the Gaza strip. Data were collected and nasopharyngeal swabs were obtained. Antibiotic
susceptibilities were determined by Vitek-2 and serotypes by the Quellung reaction.
Principal Findings: S. pneumoniae carriage was detected in 189/379 (50%) of children and 30/376 (8%) of parents. Carriage
prevalence was highest in children ,6 months of age (63%). Significant predictors for child carriage were number of
household members and DCC attendance. The proportion of pediatric and adults isolates with serotypes included in PCV7
were 32% and 20% respectively, and 46% and 33% in PCV13 respectively. The most prominent non-vaccine serotypes (NVT)
were 35B, 15B/C and 23B. Penicillin-nonsusceptible strains were carried by70% of carriers, penicillin-resistant strains (PRSP)
by 13% and Multi-drug-resistant (MDR) by 30%. Of all PRSP isolates 54% belonged to serotypes included in PCV7 and 71% in
the PCV13. Similarly, 59% and 73% of MDR-SP isolates, would theoretically be covered by PCV7 and PCV13, respectively.
Conclusions: This study demonstrates that, PCV13-included strains were carried by 46% and 33% of pediatric and adult
subjects respectively. In the absence of definitive data regarding the virulence of the NVT strains, it is difficult to predict the
effect of PCVs on IPD in this region.
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Introduction
S. pneumoniae is the primary cause of bacterial infections in
children, causing over 860,000 deaths a year in children
worldwide [1]. Nasopharyngeal colonization is the first and
necessary stage prior to infection, and serves as the source of
transmission between person to person [2]. Thus, to understand
the epidemiology and spread of pneumococcal infections it is
important to study the epidemiology of S. pneumoniae colonization.
Since 2000, universal vaccination with the 7-valent pneumo-
coccal conjugate vaccine (PCV7) of children ,5 years has been
implemented in the USA. Following the introduction of this
vaccine, a dramatic decrease in invasive pneumococcal infections
was observed in the USA [3]. Since most developing countries
have not yet implemented universal vaccination with this vaccine,
it is as yet unknown whether a similar effect will be observed in
countries where the incidence of disease is even higher.
The Palestinian-Israeli collaborative research (PICR) group was
established to study the direct, indirect and potential effects of
PCV7 on Israeli and Palestinian populations.
The Gaza strip is a 360-km
2 narrow area located on the Eastern
coast of the Mediterranean Sea. The strip borders Egypt on the
south, the Mediterranean on the west and Israel on the north and
east. It is populated by about 1.5 million inhabitants. The annual
population growth rate is 3.3%, and the infant mortality rate is
,20/1000 (UNRWA data: http://unispal.un.org/UNISPAL.
NSF/0/885BD85F 892778F28525772700503A4B). Poverty, large
families (average family size, 7.5persons) and overcrowding are
prevalent. Health care is provided by the Palestinian Ministry of
Health Services, and the United Nations Relief and Works Agency
(UNRWA) Health Department as well as private and charitable
sources. No PCV has yet been introduced in the Gaza strip; the
implementation of universal vaccination with either PCV7,
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by the Palestinian Authority.
The epidemiology of S. pneumoniae carriage in the Gaza strip has
not yet been studied. In this study we assessed the prevalence of S.
pneumoniae carriage in the Gaza strip.
Methods
Study population and site
The surveillance took place between March and July
2009.Children under 5.5 years of age, who lived in 12
neighborhoods or villages in north and central Gaza strip were
randomly selected. The parents were contacted and asked to
participate in the study; if consent was given, a research assistant
then visited the family to obtain signed consent. Only one child
and one parent were enrolled from each family. The study was
approved by the institutional review boards of Macabbi Health-
care Services and the Gaza ministry of health.
Data Collection
Parents were interviewed to collect the following demographic
and medical information: age and gender of the child and parent,
number of household members, number of siblings, age of siblings,
day care attendance of child or his siblings, working place of the
parent, smoking by any of the household members, breastfeeding,
owning pets, medical history of the child and the parent including
any chronic or recurrent illnesses, antibiotic use during the
previous month, immunizations, hospitalization during the past 6
months and medical status on the screening day.
S. pneumoniae screening
A single nasopharyngeal swab, using a rayon-tipped aluminum
shaft swab placed in Amies transport media (Copan innovation,
Brescia, Italy) was collected. Within 24 h, specimens were
transported to the Macabbi Healthcare Services central laboratory
in Israel and streaked onto tryptic soy agar plates supplemented
with sheep-blood and 5 mg/ml gentamicin and were incubated
overnight at 35uCi n5 %C O 2enriched air. S. pneumoniae was
identified using morphological characteristics, a-hemolysis and
optochin susceptibility. Antibiotic susceptibility was determined by
Vitek 2. A strain was defined as penicillin non-susceptible if the
minimum inhibitory concentration (MIC) to penicillin was
.0.06 mg/L and penicillin resistance was defined as
MIC$2 mg/L. Multi-drug resistance was defined as non-
susceptibility to at least penicillin (MIC.0.06 mg/L) and
erythromycin (MIC.0.5 mg/L). Serogroup was determined by
the latex agglutination test and the serotype was determined by the
Quellung reaction (Staten Serum Institute, Copenhagen, Den-
mark).
Statistical Analyses
Analyses were performed using SAS software package, version
9.2 (SAS Institute). Frequencies of potential predictors were
compared using x
2 or Fisher’s exact test when appropriate.
Median values were compared using the Mann-Whitney U test.
Results were considered statistically significant if the 2-tailed P
value was ,0.05. Variables assessed as predictors for carriage, or
for carriage of resistant strains included; age, gender, number of
household members, day care center (DCC) attendance, antibiotic
use during the month prior to screening, and hospitalization
during 6 months prior to screening. In the multivariate logistic
model, variables that were significant or trended towards
significance (p,0.2) were included and the adjusted odds ratio
(aOR) was assessed.
Results
Patient characteristics
Overall, 758 individuals were enrolled: 379 children and one of
their parents. Children’s age ranged from 3 weeks to 5.5 years with
a median age of 1.86 years; nearly one quarter of the children
(24%) were younger than 1 year. Female/male ratio was about
1;1. Per parental report, almost all children (96%) stayed at home
with their siblings and their family and did not attend DCC. The
median number of household members was 7 with the range of 2–
25. Fewer than 10% of the children (26, 6.9%) had no siblings
while a quarter (97 children, 25.6%) of the children had six or
more siblings. Most children (95%) completed the routine
Figure 1. S. pneumoniae carriage by age and by PCV7 vaccine type (VT7) serotypes, serotypes added to PCV7 in PCV10 (a-VT10),
serotypes added to PCV10 in PCV13 (a-VT13). Light grey-VT7 serotype carriage. Dark grey-a-VT10 (1, 5, 7F), Black – a-VT13 (3, 6A, 19A), White -
Non-VT13 carriage.
doi:10.1371/journal.pone.0035061.g001
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OPV + IPV, DPT, Hib, MMR). No child was immunized with
PCV7, which, at the time of the study, was not available in the
Gaza strip. The study parents’ age ranged from 19.5 to 58 years
with a median of 32 years. Most of the screened parents (69%)
were mothers of which 94% did not work outside of the home.
Among the 106 fathers screened 37% reported that they were
unemployed.
S. pneumoniae carriage
S. pneumoniae carriage was detected in 50% (189/379) of children
and 8% (30/376) of parents. Carriage prevalence was highest in
children ,6 months with 63% (19/30) carriage and lowest in
children aged 6–11 m with 37% (22/60) carriage. In older age
groups the carriage prevalence varied between 47% and 57%
(Figure 1).Predictors of S. pneumoniae carriage included number of
household members (aOR for each additional member 1.08; 95%
confidence interval (CI) 1.01–1.14, p=0.02) and DCC attendance
(aOR 3.72; 95%CI 0.98–14.17, p=0.05), while age 6–11 m was a
negative predictor (aOR 0.36; 95%CI 0.14–0.92, p=0.003)
(Table 1).
Potential coverage by PCV7
Only 34.4% of carried S. pneumoniae isolates in children belonged
to serotypes included in PCV7 (referred to as vaccine-types (VT7)),
while among parents the proportion of VT7 isolates was even
lower (20.0%). While 36.5% of children’s’ isolates and 20.0% of
parents’ isolates were VT10, 49.2% and 30.0% of children’s’ and
parents’ isolates respectively were VT13 strains (Figure 2). The
most frequent non-VT13 serotypes in children were 35B (5.3% of
all strains), 15B (4.8%) and 23B (2.7%), while in adults a large
diversity of non-VT13 serotypes was observed, the most common
being 6C (10.0% of all adult strains).
Antibiotic use and antibiotic resistance
Antibiotic use within the month prior to screening was reported
in 37.5% of children and 17.4% of parents. Among the cases in
which the antibiotic class that was used was known (45% of cases),
the most frequently used in children was penicillin (64%), followed
by cephalosporins (22%); macrolide use was relatively rare (6%).
Among pediatric carriage strains, 70.1% (132) were penicillin-
non-susceptible (PNSSP) and 12.8% (24) were penicillin-resistant
(PRSP). Multi-drug-resistant (MDR)S. pneumoniae strains were
carried by 56 children; this represented 30.0% of pediatric
carriage strains. The prevalence of PNSSP among carrier parents
was lower than in children (40.0%vs. 70.1%, p=0.0013), but
PRSP and erythromycin-resistance prevalence were similar to
those in children (Figure 3).
The only independent predictor for PRSP or MDR-SP carriage
by children in a multivariate logistic analysis was recent antibiotic
treatment (aOR=3.72, 95%CI 1.48–9.35 (p=.005) and
aOR=3.27, 95%CI 1.62–6.60 (p=.001) respectively). For
MDR carriage in children, male gender was also a predictor for
carrying MDR-SP (aOR=2.18, 95%CI 1.08–4.41, p=.003). No
specific antibiotic class could be defined as a particular predictor
for either antibiotic resistance patterns, but the small number of
children in each individual category may have limited the power
to detect any association.
Potential effect of PCVs on reducing antibiotic resistance
To assess the potential effect of PCVs on reducing the frequency
of antibiotic resistance in children, we examined the proportion of
PRSP and MDR-SP that belong to VT7, VT10 or VT13 strains.
Of all PRSP isolates 54.2% belonged to serotypes included in
PCV7, or PCV10 and 70.9% in the PCV13. Similarly, 58.9%of
MDR-SP isolates belong to VT7 or VT10 and 73.2% of MDR-SP
belong toVT13 serotypes (Figure 4). Of the 56 MDR-SP isolates,
the most common serotypes were 19F (17.9% of MDR isolates)
followed by 14, 6B and non-typeable serotypes (16.1% each); 15
MDR-SP isolates (26.8%) had serotypes that would not be covered
by PCV13 (non-VT13). The serogroup with the highest likelihood
of antibiotic resistance was 14: 66.7% of serogroup 14 isolates were
PRSP and 75.0% MDR; serotype 19F also had a high likelihood
of resistance, with 33.3% PRSP and 83.3% MDR. Fifty percent of
serotype 19A isolates were PRSP and 37.5% were MDR. PCV7
would cover most PNSSP except for serotypes 6A, 19A 35B and
15B; the first two serotypes would in theory be covered by PCV13.
Assuming similar effects of PCV7 on colonizing strains [4,5,6,7,8],
PCV7 and PCV10 could potentially decrease 54.2%, 58.9% and
46.2% of PRSP, MDR and PNSSP pediatric isolates, respectively;
Table 1. Predictors of S. pneumoniae carriage in children in
the Gaza strip.
Predictor N*
%S .
pneumoniae aOR p-
carriage** (95%CI) value
Age ,6months 30 63.33% REF
6–11 m 60 36.7% .36 .003
(.14–.92)
1 y 115 56.5% .81 .63
(.35–1.90)
2 y 75 46.7% 0.53 .16
(.22–1.28)
3–5.5 y 99 47.5% .47 .09
(.20–1.12)
Gender Male 187 49.2%
Female 192 49.5%
S.pneumoniae No 345 48.7% REF
carriage by parent Yes 30 60.0% 1.31 .51
(.59–2.94)
Attending DCC No 366 48.6% REF
Yes 13 76.9% 3.72 .05
(.98–14.17)
Received Abx in No 237 51.1% REF
past 6 months Yes 142 47.2% 0.86 .49
(.55–1.33)
Hospitalization in No 327 48.6%
previous 6 months Yes 52 55.8%
Number of each extra 1.08 .02
household members member (1.01–1.14)
Smoker No 257 48.1%
Yes 116 54.2%
Current No 95 50.5%
Breastfeeding Yes 103 54.4%
(amongchildren,2y )
*N=total number of children with the specified predictor.
**% S. pneumoniae carriage among children with the specific predictor.
doi:10.1371/journal.pone.0035061.t001
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73.2% and 62.1%, respectively.
Discussion
In this study we report data on S. pneumoniae carriage in
Palestinian populations living in the Gaza strip. We show that S.
pneumoniae carriage is high, particularly at a very early age.
Previous studies have showed that children below 3 months of age
are rarely S. pneumoniae carriers and that the most significant risk
factor for carriage is attending DCC [9,10,11]. The findings in the
Gaza strip are different, in that very few children attend DCC, and
yet S. pneumoniae carriage was detected at a very early age. These
findings are overall consistent with those obtained from other
developing countries, and have been attributed to the low
socioeconomic and high overcrowding conditions [12,13,14]. An
intriguing finding in our study is the significantly lower carriage
prevalence among children 6–11 months old. This unexpected
finding persists even after adjusting for potential effects of
breastfeeding or DCC attendance, a result that remains to be
explained.
The relatively low coverage of colonizing serotypes by PCV7 in
the Gaza strip shown here mirrors findings from over a decade ago
[15] and more recent studies of invasive disease in developing
world settings. In that study 97 isolates from middle ear fluid
(MEF) or CSF were assessed, 47% and 24% of isolates from MEF
and CSF, respectively, were found to belong to PCV7 strains. A
recent study of bacterial infections in children in Nigeria identified
21 cases of IPD, in which PCV7 would cover 55% of cases [16]. A
study on bacterial meningitis in Uganda identified 43% of
serotyped S. pneumoniae isolates to be covered by PCV7 [17] and
a study that followed 99 children in Bangladesh [18], showed
Figure 2. Serotype distribution among carriage strains in the Gaza strip. a. Among children. b. Among parents. Vaccine type (VT)7:
serotypes covered by PCV7, VT13: serotypes covered by PCV13. Asterix (*) - serotypes covered by PCV10 (1, 5, 7F), Non-VT13: only serotypes that are
prevalent in .2% are depicted separately.
doi:10.1371/journal.pone.0035061.g002
Figure 3. Prevalence of antibiotic resistance among isolates. Black - children. Grey - Parents. PNSSP: penicillin non-susceptible S. pneumoniae
(MIC.0.06 mg/L), PRSP: penicillin resistant S. pneumoniae (MIC$2.0 mg/L), ERSP: erythromycin resistant S. pneumoniae (MIC.0.5 mg/L), TMP/SXTR-
SP: trimethoprim-sulfamethoxazolenon-susceptible S. pneumoniae (MIC.0.5 mg/L),MDR-SP: multi-drug resistant S. pneumoniae, defined as non-
susceptible to at least penicillin and erythromycin.
doi:10.1371/journal.pone.0035061.g003
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defined, and serogroups were used to approximate PCV7
coverage.
There has been a call for the rapid implementation of PCV7 in
developing countries [19], mainly based on the success of this
vaccine in the US and Europe, and two clinical trials that have
demonstrated impressive efficacy of PCV9 in developing countries
[20,21]. How effects observed in controlled clinical trials will
translate to situations of universal immunization in developing
regions is unclear and will need to be studied [22]. Since January
2010 two countries supported by Gavi alliance for pneumococcal
vaccines have introduced PCV7 into routine childhood immuni-
zation (the Gambia and Rwanda) [23]; the results of this important
intervention are eagerly awaited.
We readily acknowledge that the limitation that our study
focuses on carriage serotypes only and not invasive disease strains.
However, carriage data has been used to estimate IPD using the
relative invasive capacity of the different serotypes [24]. It appears
that the invasive capacity of serotypes do not vary significantly
across different populations [25,26,27], and thus carriage data
could well be used to predict the potential effect of PCVs in this
region as well.
On the other hand, the possibility remains that despite the
relatively low coverage by PCV7 of pediatric carriage strains in the
Gaza strip, the introduction of a PCV in the region could have an
important clinical impact. While it appears that PCV7 will cover
only 30% of pediatric colonization strains, a 30% decrease in these
strains may translate to more reduction of disease, since it appears
that these VT7 strains are associated with more virulence and
morbidity than some of the other NVT strains [3,22,28]. An
unknown factor, and one that cannot be readily ascertained from
the result of vaccine trials, is to what extent and how fast will
replacement disease by non-VT strains occur following universal
immunization. It is also unclear whether the extent of replacement
is dependent on the pre-vaccination PCV7 coverage [22] (30% in
Gaza compared to ,90% in USA).
It has also been reported that pneumococcal carriage that
occurs shortly before the first PCV7 dose may result in hypo-
responsiveness to the carried strain serotype [29], a finding which,
if applicable broadly, may have a greater impact in developing
countries and in the Gaza strip, where colonization occurs at a
much earlier age.
Another potential benefit of the introduction of PCVs would be
to reduce antibiotic resistance, as has been noted in several
countries [6,30,31,32,33]. It should be noted however that, in
regions where PCV7 has been implemented and antibiotic
resistance patterns were followed, the effect of PCV7 on lowering
antibiotic resistance tend to be rather short-lived, if not
accompanied by concurrent reduction in antibiotic use
[7,34,35,36]. High antibiotic use was reported in our study
population. Since only 45% of the subjects who reported antibiotic
use could specify the antibiotic name or class used, we cannot be
certain that there may have been some misclassification of other
medicines as antibiotics by the subjects. That said, the high
antibiotic resistance prevalence is indeed suggestive of actual high
antibiotic consumption. In any case, a concerted effort to reduce
antibiotic use should also be included in a vaccination campaign in
the Gaza strip.As in other parts of the world, much of the
antibiotics in this region are obtained by over-the-counter
purchase, which may complicate any efforts to curtail inappro-
priate antibiotic use.
In conclusion, our study reports the prevalence of S. pneumoniae
carriage in the Gaza strip, the prevalence of VT7, VT10 and
VT13 strains and the prevalence of antibiotic resistant strains. As
has been observed in other settings in the developing world, the
potential coverage of PCVs against colonization strains is not as
high as in the US or Western Europe. The evolving epidemiology
of pneumococcal colonization and disease in the Gaza strip will
need to be monitored closely and over time, to assess the real
impact of the introduction of PCVs in this region.
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